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Devices in Heart Failure
Potential Methods for Device-Based  
Monitoring of Congestive Heart Failure
Congestive heart failure has long been one of the most serious medical conditions in 
the United States; in fact, in the United States alone, heart failure accounts for 6.5 mil-
lion days of hospitalization each year. One important goal of heart-failure therapy is to in-
hibit the progression of congestive heart failure through pharmacologic and device-based 
therapies. Therefore, there have been efforts to develop device-based therapies aimed at 
improving cardiac reserve and optimizing pump function to meet metabolic requirements. 
The course of congestive heart failure is often worsened by other conditions, including 
new-onset arrhythmias, ischemia and infarction, valvulopathy, decompensation, end- 
organ damage, and therapeutic refractoriness, that have an impact on outcomes. The onset 
of such conditions is sometimes heralded by subtle pathophysiologic changes, and the 
timely identification of these changes may promote the use of preventive measures. Con-
sequently, device-based methods could in the future have an important role in the timely 
identification of the subtle pathophysiologic changes associated with congestive heart fail-
ure. (Tex Heart Inst J 2008;35(2):166-73)
ongestive heart failure (CHF), long one of the nation’s most serious medical 
problems, contributes to approximately 250,000 deaths each year. About 2% 
of the total population has CHF, and it accounts for about $20 billion an-
nually in health-care expenses. In the United States alone, heart failure accounts for 
6.5 million days of hospitalization annually.1,2 The mean length of hospital stay for a 
CHF-related admission is approximately 14 days.1
 One important goal of heart-failure therapy is to inhibit the progression of CHF 
through pharmacologic and device-based therapies. Accordingly, there have been in-
tensive efforts to develop device-based therapies aimed at improving cardiac reserve 
and optimizing pump function to meet metabolic requirements. The fairly indolent 
course of CHF is often worsened by overriding perturbations, including new-onset ar-
rhythmias, ischemia and infarction, valvulopathy, decompensation, end-organ dam-
age, and therapeutic refractoriness, which have an impact on outcomes. For example, 
mortality rates are 34% higher in CHF patients who have atrial fibrillation than in 
patients who have CHF alone.3
 The onset of conditions known to worsen patients’ prognoses is sometimes herald-
ed by subtle pathophysiologic changes. The timely identification of such changes can 
enable preventive measures, and device-based methods should have an important role 
in this process.
 The purpose of the present review is to survey the pathophysiologic processes that 
can now be monitored by mechanical devices and to provide information about pre-
dicting the onset of a condition that can aggravate CHF. In the interest of brevity (in 
dealing with a vast subject), we will discuss only those select pathologic conditions 
that occur frequently in CHF patients and adversely affect outcomes. Table I provides 
a summary of devices and procedures that have the potential of predicting these ad-
verse events.
New-Onset Atrial Fibrillation
Atrial fibrillation (AF) and CHF tend to coexist, and the prevalence of AF increas-
es in parallel with the severity of CHF.4 Atrial fibrillation may affect as few as 5% of 
CHF patients with mild disease3 and as many as 50% with New York Heart Associ-
ation (NYHA) functional class IV symptoms.5 In a study of 1,470 Framingham par-
ticipants who developed AF, CHF, or both, 382 (26%) developed both, and 41% 
of that number had CHF first.6 These statistics correlate with reports of AF preva-
lence published elsewhere.7 Although some studies have shown variability in the asso-
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ciation between AF and increased death, other studies 
have shown that AF plays an important role in predict-
ing death.8,9 The impact of AF on CHF death (Fig. 1) 
is particularly significant if the CHF is mild10 or if car-
diac decompensation is present.11
 The development of AF in CHF patients can be ex-
plained by impaired hemodynamics, an altered neu-
rohumoral state, and an acute rise in atrial pressure, 
all of which promote electrical and structural remod-
eling and elicit mechanoelectrical feedback within the 
TABLE I. Devices in Heart Failure
               Condition Device or Procedure How Future Events Are Predicted
Atrial fibrillation Periodic 2D echocardiography Measures increased atrial diameter (>40 mm), 
     low left ventricular fractional shortening, left 
     ventricular wall thickness
Right ventricular dysfunction Periodic 2D echocardiography Measures RVWT ≥0.8 mm, RVEDD >6 mm,  
     TAPSE <1.6 mm, PAAT/CL ratio <0.08
Nonischemic cardiomyopathy Electrical impedance spectroscopy Measures changes in myocardial resistance 
     secondary to ischemia
 Intracardiac electrocardiography Measures changes in myocardial resistance 
     secondary to ischemia
CAD/ischemia Peak endocardial acceleration Measures changes in myocardial resistance 
     secondary to ischemia
 Coronary sinus thermometry May show increased coronary sinus tempera-  
     ture with ischemic/obstructive CAD
 Ballistocardiography Noninvasively records the stroke volume of the  
     heart for calculating cardiac output
 Seismocardiography Noninvasively records cardiac vibrations and 
     measures acute and chronic changes in left 
     ventricular function
 Strain-rate imaging Measures the timing and extent of myocardial 
     deformation and provides more reliable 
     information about the sequence of myocardial 
     contraction in the presence of delayed  
     electrical activation
Cardiac decompensation Noninvasive impedance cardiography Measures TFC and changes in thoracic electrical 
     impedance as a consequence of TFC
 OptiVol Monitors thoracic impedance through biventric- 
     ular pacemaker electrodes and gives a general  
     indication of the fluid balance of patients; help- 
     ful in predicting impending volume overload
 HeartPOD Measures left atrial pressures and provides an 
     indirect estimate of PCWP in impending 
     decompensation
 Hypothermia May serve as a univariate predictor of in-hospital 
     death in patients with CHF decompensation  
     and may also serve to predict CHF  
     decompensation
 Chronicle Measures right ventricular pressures and  
     estimated pulmonary artery diastolic pressure  
     through a lead implanted in the right ventricu- 
     lar outflow tract
Sudden cardiac death Implantable defibrillators Primary and secondary prevention
 Signal-averaged electrocardiography Risk stratification
 T-wave alternans Risk stratification
 Heart rate variability Risk stratification
 
CAD = coronary artery disease; CHF = congestive heart failure; PAAT/CL = pulmonary artery acceleration time/cycle length; 
PCWP = pulmonary capillary wedge pressure; RVEDD = right ventricular end-diastolic dimension; RVWT = right ventricular 
free-wall thickness; SCD = sudden cardiac death; TAPSE = tricuspid excursion; TFC = thoracic fluid content; 2-D = 2-dimen-
sional
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atria.12,13 Structural remodeling, including fibrosis and 
dilatation, is, at some level, mediated by humoral fac-
tors such as angiotensin.10 Potent profibrotic molecules 
such as angiotensin II, which circulate abundantly in 
the bloodstreams of CHF patients, promote the disper-
sion of atrial impulse conduction and re-entry by alter-
ing the atrial ultrastructure.14
 In a prospective study conducted in Framingham 
participants to determine which impaired mechanics 
of cardiac activity lead to AF, an analysis of echocar-
diographic data showed that increased atrial diameter, 
increased left ventricular wall thickness, and low left ven-
tricular fractional shortening were predictive of AF.15 
The study’s conclusions, however, were reached on the 
basis of periodic echocardiographic measurements and 
lacked information on serial changes in the described 
echocardiographic values. Therefore, the study was in-
conclusive in describing rates of change and cut-off 
points in the echocardiographic measurements of in-
terest. However, others have shown that left atrial di-
ameters >40 mm are indeed associated with increased 
risk of AF.16
 It should be noted that cardiac biometry varies with 
an individual’s height; therefore, in clinical practice, 
it may not be feasible to apply cut-off points. Rates of 
change in variables that one predictive of future AF 
may be a more effective indication and afford a better 
standard. Measurement of such variables and their rates 
of change could be achieved with continuous monitor-
ing devices, which could prove useful in the early iden-
tification of high-risk patients.
New-Onset Right Ventricular Dysfunction
Right ventricular dysfunction may constitute the “com-
mon final pathway” in the progression of CHF.17 How-
ever, there are no clear data to describe the epidemiology 
and pathophysiology of right ventricular dysfunction 
and how it complicates the prognoses of patients with 
pre-existing left ventricular dysfunction. Inferences can 
be made from studies that recruited patients with iso-
lated left ventricular dysfunction, in whom right ven-
tricular dysfunction could develop as their disease 
progressed.18 The anatomically united ventricles exhibit 
mechanical coupling, in which the performance of one 
ventricle has an effect on the other. This mechanical in-
terdependence is another means by which a pathologic 
process can be diffused.19,20
 A study by Mariano-Goulart and associates21 deter-
mined that there is a correlation between high levels 
of brain natriuretic peptide and right ventricular dys-
function. That study compared plasma brain natriure-
tic peptide (BNP) levels in patients who had isolated 
left ventricular dysfunction with levels in patients who 
had biventricular dysfunction and found that right-sid-
ed heart failure contributed substantially to the eleva-
tion of BNP. The authors concluded that important 
BNP increases in patients with “isolated” left ventricular 
dysfunction should indicate a high risk of right ventric-
ular dysfunction. From the results of another study, by 
Ahmed and colleagues,22 it may be inferred that approx-
imately 35% of CHF patients have isolated left ventric-
ular dysfunction. Therefore, a fairly large population of 
patients with lone left-sided failure may eventually de-
velop right ventricular dysfunction during the course of 
their disease.
 Other studies of the prognostic impact of right ven-
tricular dysfunction reveal its importance in predicting 
functional capacity and short-term outcomes in CHF 
patients.23-27 In a prospective study of the role of right 
ventricular ejection fraction (RVEF) in predicting short-
term outcomes in 142 ambulatory patients who were 
awaiting cardiac transplantation, an RVEF <24% was 
found to be predictive of a greater death rate.28 In addi-
tion, survival and symptoms are worse in patients with 
dilated cardiomyopathy and biventricular failure than 
in patients whose RVEF is close to normal (>35%).25 
In another study, RVEF together with NYHA classifi-
cation and functional capacity were predictive of surviv-
al in patients with mild-to-moderate CHF symptoms.23 
Right ventricular function remains important in pre-
dicting functional capacity and short-term outcomes, 
particularly in very ill patients for whom the left ventric-
ular ejection fraction (LVEF) is not as reliable for pre-
dicting those same outcomes (Fig. 2). The evaluation of 
right ventricular systolic and diastolic function provides 
complementary information, with a very high power to 
stratify the prognoses of patients with heart failure.26
 Despite its powerful prognostic implications, the right 
ventricle is not as well studied as the left.17 Data on right 
ventricular pathophysiology have been drawn from an-
imal models of right ventricular dysfunction. Hardzi-
yenka and coworkers24 studied the progressive changes 
in selected echocardiographic variables that preceded 
Fig. 1  New-onset atrial fibrillation is associated with increased 
risk of death in congestive heart failure. (Reprinted with permis-
sion from Swedberg K, Olsson LG, Charlesworth A, Cleland 
J, Hanrath P, Komajda M, et al. Prognostic relevance of atrial 
fibrillation in patients with chronic heart failure on long-term treat-
ment with beta-blockers: results from comet. Eur Heart J 2005; 
26[13]:1303-8.)
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right-sided heart failure in rats. All variables deteriorated 
progressively: right ventricular free-wall thickness, ≥0.8 
mm; right ventricular end-diastolic diameter, >6 mm; 
tricuspid excursion, <1.6 mm; and pulmonary artery 
acceleration time normalized to cycle length (PAAT/
CL ratio), <0.08. Interestingly, the deterioration pre-
ceded the development of overt right-sided heart failure 
and followed a distinct temporal sequence. The investi-
gators concluded that these variables were useful in pre-
dicting the onset of right ventricular failure in rats and 
that their applicability to human beings should be in-
vestigated.24
 These methods and variables may be used for device-
based monitoring that could facilitate the prediction of 
right ventricular dysfunction before the onset of overt 
right-sided heart failure in patients with pre-existing dis-
ease.
New-Onset Ischemia in  
Nonischemic Congestive Heart Failure
There is a distinct paucity of data on the incidence of 
new-onset coronary artery disease in patients who al-
ready have a diagnosis of nonischemic CHF. Coronary 
artery disease (CAD) is a real and possibly under-recog-
nized phenomenon in nonischemic CHF. For heart-
failure patients in whom the ischemic portion of the 
disease has escaped notice, there is risk of future isch-
emia and infarction. The risks of ischemic complica-
tions in these patients and the affect on outcomes are 
unknown,29 as is the contribution of CHF to atherogen-
esis and CAD. Vague estimates of the incidence of isch-
emia and infarction in nonischemic CHF patients may 
be made on the basis of data available from some clinical 
trials.30,31 However, these estimates have inherent limi-
tations—mainly that the diagnostic methods used in 
classifying CHF populations into ischemic and nonis-
chemic subgroups yield high numbers of false positives 
for ischemia.32 In addition, an ischemic episode can ap-
pear to be sudden cardiac death (SCD) in the already-
weakened heart. In such cases, a diagnosis is made only 
at autopsy, which is not routinely performed. In a search 
of the medical literature, we found no studies other than 
clinical trials that provided data on the epidemiology of 
new-onset CAD in nonischemic CHF patients. The 
manifestation rate of CAD averaged 7% to 12% per le-
sion per year.33,34
 Although devices that detect electrical and mechani-
cal changes in the heart may show the presence of isch-
emia, there are other potential detection methods for 
use in implantable devices. Electrical impedance spec-
troscopy, for example, measures changes in myocardial 
resistance that are secondary to ischemia. This method 
has been used in the diagnosis of several diseases, in-
cluding breast cancer, cervical cancer, and tumors of the 
urothelium, in addition to myocardial ischemia.35 Repo-
larization abnormalities are also often used for diagnos-
ing ischemia, and these changes are measurable through 
intracardiac and intracoronary approaches. Intracardiac 
electrocardiography (ECG) has been found to be more 
sensitive than surface ECG and to show ischemic re-
sponses earlier, even in the presence of intraventricu-
lar conduction delays (for example, left bundle-branch 
block).36 Electrocardiography performed with electrodes 
placed within the coronary arteries also provides in-
creased sensitivity and specificity.37 Other methods of 
detecting ischemia include peak endocardial accelera-
tion measurement, coronary sinus thermometry, bal-
listocardiography, seismocardiography, and strain-rate 
imaging.38-42
 Guidelines for the clinical monitoring of CAD are 
well defined in the medical literature. At the same time, 
considerable work is being done to decrease morbidity 
and death associated with ischemia. Real-time, device-
based monitoring, although not routinely used, may be 
beneficial in high-risk patients, particularly those whose 
hearts are already compromised and least able to sustain 
a superimposed myocardial insult.
Decompensation
Cardiac decompensation is a “period of broken com-
pensation” associated with “embarrassed circulation”43 
and characterized by reduced cardiac output, hypo-
perfusion, tissue congestion, and an increased pulmo-
nary capillary wedge pressure. Numerous precipitating 
factors may worsen cardiac function and volume sta-
tus, resulting in an episode of acute decompensation.44 
However, a large number of decompensation cases (up 
to 34%) occur in the absence of identifiable precipitat-
ing factors.45,46 Outcomes after hospitalization for de-
Fig. 2  Right ventricular dysfunction in congestive heart failure. 
Group 4 = depressed right ventricular ejection fraction (RVEF) 
and elevated pulmonary arterial pressure (PAP). Group 1 = pre-
served RVEF and normal PAP. Groups 2 and 3 = at least one fac-
tor (RVEF or PAP) is impaired. (Reprinted with permission from 
Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, 
et al. Independent and additive prognostic value of right ventric-
ular systolic function and pulmonary artery pressure in patients 
with chronic heart failure. J Am Coll Cardiol 2001;37[1]:183-8.)
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compensation are poor: mortality rates are 37% for men 
and 30% for women after 1 year of follow-up.47 Rates of 
rehospitalization range from approximately 30% within 
60 days after discharge45 to 44% at 6 months.48
 The period between symptom onset and hospitaliza-
tion is usually characterized by a gradual deterioration, 
which may be as short as 3 days among elderly patients49 
or as long as 2 weeks among younger patients.50 This pe-
riod could provide an important “window” for moni-
toring values that are predictive of decompensation, and 
the development of mechanical devices that are capable 
of such monitoring could lead to improved outcomes. 
Noninvasive impedance cardiography uses changes in 
thoracic electrical impedance to measure thoracic fluid 
content,51 and studies have shown that this technolo-
gy is effective in predicting the increased near-term 
(14-day) risk of recurrent decompensation, impend-
ing hospitalization, or SCD.52 OptiVol (Medtronic, 
Inc.; Minneapolis, Minn), a system used in conjunction 
with biventricular pacemakers, monitors thoracic im-
pedance through pacemaker electrodes; it is currently 
being tested in clinical trials (MiD-HeFT and FAST). 
The HeartPOD can be percutaneously implanted in-
side the left atrium, where it directly measures left atrial 
pressures and can monitor impending decompensation 
as signaled by rapid increases in pulmonary capillary 
wedge pressure and left atrial pressure. It can also pro-
vide information about the appropriate titration of med-
ications until left atrial pressures are optimized.53 The 
device is currently being investigated in a clinical trial 
(homeostasis) that is aimed at showing the efficacy of 
frequent-dose titration on the basis of left atrial pres-
sure variation.
 Low body temperature is a novel indicator of poor 
prognosis in CHF patients. Our team has shown that 
low body temperature is a univariate predictor of in-
hospital death in patients with decompensation.54 The 
prognostic role of body temperature in predicting death 
in CHF patients has been published elsewhere.48 Exten-
sive work is now being done to identify the predictive 
role of low body temperature in various clinical settings. 
Data have shown that CHF patients who experience a 
decrease in body temperature over time require rehos-
pitalization.55 On the basis of existing data and ongoing 
work, body-temperature monitoring may gain accep-
tance as an inexpensive but sensitive method for device-
based monitoring in CHF patients.
 The Chronicle (Medtronic) is an implantable de-
vice that is programmed to measure right ventricular 
pressures and to estimate pulmonary artery diastol-
ic pressure through a lead implanted in the right ven-
tricular outflow tract.56 Results from initial studies are 
encouraging.57 Right ventricular hemodynamic moni-
toring with Chronicle modestly reduced CHF-related 
events by 22% (P=NS). A subset of CHF patients with 
NYHA functional class III symptoms benefited most 
from Chronicle, with a 41% reduction in CHF-relat-
ed events (P <0.05).58
 Acute decompensation in CHF is a life-threaten-
ing condition. Although our ability to predict future 
decompensation in patients is limited, the use of some 
mechanical devices for measuring certain physiologic 
variables may prove invaluable for predicting which pa-
tients are most at risk in the near-term.
Sudden Cardiac Death
Sudden cardiac death accounts for 300,000 to 400,000 
deaths in the United States each year.59 A large number 
of deaths in CHF patients can be attributed to SCD (al-
most 30% in dilated cardiomyopathy).60 In a study of 
more than 3,000 consecutive patients who underwent 
cardiopulmonary resuscitation for SCD, the survival 
rate was 1.4% until hospital discharge.61 In addition, up 
to 80% of SCD survivors may have anoxic encephal-
opathy.
 The advent of implantable cardioverter-defibrillators 
(ICDs) has had a beneficial effect on outcomes. Several 
clinical trials have shown improved freedom from all-
cause mortality after ICD implantation.62 In the Mul-
ticenter Automatic Defibrillator Implantation Trial 
(MADIT), there was a 56% reduction in death among 
patients who had an ICD.63
 Two noninvasive electrocardiographic tools are being 
used clinically for identifying patients at risk of SCD: 
signal-averaged electrocardiography and T-wave alter-
nans (Fig. 3).64
 One measurable mechanism for possible device-based 
monitoring is a reduction in heart rate variability, in 
response to alterations in autonomic tone. Heart rate 
variability is studied by time-domain or frequency- 
Fig. 3  Significantly elevated T-wave alternans ratios in patients 
susceptible to inducible ventricular arrhythmias. (Reprinted with 
permission from Rosenbaum DS, Jackson LE, Smith JM, Garan 
H, Ruskin JN, Cohen RJ. Electrical alternans and vulnerability to 
ventricular arrhythmias. N Engl J Med 1994;330[4]:235-41.) 
 
OHD = organic heart disease; EP Test = electrophysiologic 
stimulation of arrhythmias
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domain analysis. Vagal tone on the heart can be mea-
sured by indices of heart rate variability that are derived 
by frequency-domain analysis—that is, low-frequency 
and high-frequency power domains. The frequency do-
mains may then be used in the diagnosis of reduced 
vagal tone or increased sympathetic tone on the heart, 
both of which are arrhythmogenic disorders.65 Heart 
rate variability must be considered with the absolute val-
ues of both low and high frequency to determine what 
factor contributes to the autonomic misbalance and po-
tential arrhythmogenesis.
Conclusions
Despite advances in the management of CHF patients, 
clinical practice still lacks the monitoring and diagnos-
tic methods that have substantial specificity and sensi-
tivity: for example, acute decompensated heart failure 
is still diagnosed by physical examination. Optimal 
management of CHF would reduce death and morbid-
ity, but such management requires close monitoring of 
CHF patients, with the objective of preventing the con-
ditions known to affect outcomes adversely. The de-
velopment of devices designed to predict complications 
by measuring the subtle pathophysiologic processes in-
volved in CHF may provide the foundation for future 
monitoring and diagnostic methods.
References
  1. Windham BG, Bennett RG, Gottlieb S. Care management 
interventions for older patients with congestive heart failure. 
Am J Manag Care 2003;9(6):447-59; quiz 460-1.
  2. Zannad F, Adamopoulos C, Mebazaa A, Gheorghiade M. 
The challenge of acute decompensated heart failure. Heart 
Fail Rev 2006;11(2):135-9.
  3. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw 
MA, Stevenson LW. Atrial fibrillation is associated with an 
increased risk for mortality and heart failure progression in 
patients with asymptomatic and symptomatic left ventricular 
systolic dysfunction: a retrospective analysis of the solvd tri-
als. Studies of Left Ventricular Dysfunction. J Am Coll Car-
diol 1998;32(3):695-703.
  4. Daubert JC. Introduction to atrial fibrillation and heart fail-
ure: a mutually noxious association. Europace 2004;5 Suppl 1: 
S1-4.
  5. Effects of enalapril on mortality in severe congestive heart fail-
ure. Results of the Cooperative North Scandinavian Enalapril 
Survival Study (consensus). The consensus Trial Study 
Group. N Engl J Med 1987;316(23): 1429-35.
  6. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et 
al. Temporal relations of atrial fibrillation and congestive heart 
failure and their joint influence on mortality: the Framing-
ham Heart Study. Circulation 2003;107(23):2920-5.
  7. Stevenson WG, Stevenson LW. Atrial fibrillation and heart fail-
ure--five more years. N Engl J Med 2004;351(23):2437-40.
  8. Mathew J, Hunsberger S, Fleg J, McSherry F, Williford W, 
Yusuf S. Incidence, predictive factors, and prognostic sig-
nificance of supraventricular tachyarrhythmias in congestive 
heart failure. Chest 2000;118(4):914-22.
  9. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic 
significance of atrial fibrillation in advanced heart failure. A 
study of 390 patients. Circulation 1991;84(1):40-8.
10. Schoonderwoerd BA, Van Gelder IC, Van Veldhuisen DJ, 
Van den Berg MP, Crijns HJ. Electrical and structural remod-
eling: role in the genesis and maintenance of atrial fibrillation. 
Prog Cardiovasc Dis 2005;48(3):153-68.
11. Koitabashi T, Inomata T, Niwano S, Nishii M, Takeuchi I, 
Nakano H, et al. Paroxysmal atrial fibrillation coincident 
with cardiac decompensation is a predictor of poor prognosis 
in chronic heart failure. Circ J 2005;69(7):823-30.
12. Calkins H, el-Atassi R, Leon A, Kalbfleisch S, Borganelli M, 
Langberg J, Morady F. Effect of the atrioventricular relation-
ship on atrial refractoriness in humans. Pacing Clin Electro-
physiol 1992;15(5):771-8.
13. Chen YJ, Tai CT, Chiou CW, Wen ZC, Chan P, Lee SH, 
Chen SA. Inducibility of atrial fibrillation during atrioven-
tricular pacing with varying intervals: role of atrial electro-
physiology and the autonomic nervous system. J Cardiovasc 
Electrophysiol 1999;10(12):1578-85.
14. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibril-
lation by heart failure in dogs: atrial remodeling of a different 
sort. Circulation 1999;100(1):87-95.
15. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardi-
ographic predictors of nonrheumatic atrial fibrillation. The 
Framingham Heart Study. Circulation 1994;89(2):724-30.
16. Henry WL, Morganroth J, Pearlman AS, Clark CE, Red-
wood DR, Itscoitz SB, Epstein SE. Relation between echocar-
diographically determined left atrial size and atrial fibrillation. 
Circulation 1976;53(2):273-9.
17. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon 
MD, Meldrum DR, et al. Right ventricular function and 
failure: report of a National Heart, Lung, and Blood Institute 
working group on cellular and molecular mechanisms of right 
heart failure. Circulation 2006;114(17):1883-91.
18. Ooi H, Colucci WS, Givertz MM. Endothelin mediates in-
creased pulmonary vascular tone in patients with heart failure: 
demonstration by direct intrapulmonary infusion of sitaxsen-
tan. Circulation 2002;106(13):1618-21.
19. Di Salvo TG, Mathier M, Semigran MJ, Dec GW. Preserved 
right ventricular ejection fraction predicts exercise capacity 
and survival in advanced heart failure. J Am Coll Cardiol 
1995;25(5):1143-53.
20. Feneley MP, Gavaghan TP, Baron DW, Branson JA, Roy PR, 
Morgan JJ. Contribution of left ventricular contraction to the 
generation of right ventricular systolic pressure in the human 
heart. Circulation 1985;71(3):473-80.
21. Mariano-Goulart D, Eberle MC, Boudousq V, Hejazi-
Moughari A, Piot C, Caderas de Kerleau C, et al. Major in-
crease in brain natriuretic peptide indicates right ventricular 
systolic dysfunction in patients with heart failure. Eur J Heart 
Fail 2003;5(4):481-8.
22. Ahmed A, Nanda NC, Weaver MT, Allman RM, DeLong 
JF. Clinical correlates of isolated left ventricular diastolic dys-
function among hospitalized older heart failure patients. Am J 
Geriatr Cardiol 2003;12(2):82-9.
23. de Groote P, Millaire A, Foucher-Hossein C, Nugue O, 
Marchandise X, Ducloux G, Lablanche JM. Right ventric-
ular ejection fraction is an independent predictor of survival 
in patients with moderate heart failure. J Am Coll Cardiol 
1998;32(4):948-54.
24. Hardziyenka M, Campian ME, de Bruin-Bon HA, Michel 
MC, Tan HL. Sequence of echocardiographic changes dur-
ing development of right ventricular failure in rat. J Am Soc 
Echocardiogr 2006;19(10):1272-9.
25. La Vecchia L, Paccanaro M, Bonanno C, Varotto L, Ometto 
R, Vincenzi M. Left ventricular versus biventricular dysfunc-
Volume 35, Number 2, 2008172      Device-Based Monitoring of CHF
tion in idiopathic dilated cardiomyopathy. Am J Cardiol 1999; 
83(1):120-2, A9.
26. Meluzin J, Spinarova L, Hude P, Krejci J, Dusek L, Vitovec J, 
Panovsky R. Combined right ventricular systolic and diastolic 
dysfunction represents a strong determinant of poor progno-
sis in patients with symptomatic heart failure. Int J Cardiol 
2005;105(2):164-73.
27. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos 
GS, Jondeau G, et al. Executive summary of the guidelines on 
the diagnosis and treatment of acute heart failure: the Task 
Force on Acute Heart Failure of the European Society of Car-
diology. Eur Heart J 2005;26(4):384-416.
28. Gavazzi A, Berzuini C, Campana C, Inserra C, Ponzetta M, 
Sebastiani R, et al. Value of right ventricular ejection fraction 
in predicting short-term prognosis of patients with severe 
chronic heart failure. J Heart Lung Transplant 1997;16(7): 
774-85.
29. Hedrich O, Jacob M, Hauptman PJ. Progression of coronary 
artery disease in non-ischemic dilated cardiomyopathy. Coron 
Artery Dis 2004;15(5):291-7.
30. Effect of enalapril on mortality and the development of heart 
failure in asymptomatic patients with reduced left ventricu-
lar ejection fractions. The solvd Investigators [published er-
ratum appears in N Engl J Med 1992;327(24):1768]. N Engl 
J Med 1992;327(10):685-91.
31. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, 
Horowitz JD, Massie BM, et al. Comparative effects of low 
and high doses of the angiotensin-converting enzyme inhibi-
tor, lisinopril, on morbidity and mortality in chronic heart fail-
ure. atlas Study Group. Circulation 1999;100(23):2312-8.
32. Dunn RF, Uren RF, Sadick N, Bautovich G, McLaughlin A, 
Hiroe M, Kelly DT. Comparison of thallium-201 scanning in 
idiopathic dilated cardiomyopathy and severe coronary artery 
disease. Circulation 1982;66(4):804-10.
33. Bruschke AV, Kramer JR Jr, Bal ET, Haque IU, Detrano RC, 
Goormastic M. The dynamics of progression of coronary 
atherosclerosis studied in 168 medically treated patients who 
underwent coronary arteriography three times. Am Heart J 
1989;117(2):296-305.
34. Lichtlen PR, Nikutta P, Jost S, Deckers J, Wiese B, Rafflen-
beul W. Anatomical progression of coronary artery disease in 
humans as seen by prospective, repeated, quantitated coronary 
angiography. Relation to clinical events and risk factors. The 
intact Study Group. Circulation 1992;86(3):828-38.
35. Gebhard MM, Gersing E, Brockhoff CJ, Schnabel PA, 
Bretschneider HJ. Impedance spectroscopy: a method for sur-
veillance of ischemia tolerance of the heart. Thorac Cardio-
vasc Surg 1987;35(1):26-32.
36. Siegel S, Brodman R, Fisher J, Matos J, Furman S. Intracar-
diac electrode detection of early or subendocardial ischemia. 
Pacing Clin Electrophysiol 1982;5(6):892-902.
37. Yajima J, Saito S, Honye J, Takayama T, Ozawa Y, Kanmat-
suse K. Intracoronary electrocardiogram for early detection 
of myocardial viability during coronary angioplasty in acute 
myocardial infarction. Int J Cardiol 2001;79(2-3):293-9.
38. Elsbach H, Rodrigo FA, Weeda HW, Pool J. The ballisto-
cardiogram in selection for and assessment of physical condi-
tioning in patients with ischemic heart disease. Bibl Cardiol 
1969;26:49-51.
39. Korzeniowska-Kubacka I, Bilinska M, Piotrowicz R. Useful-
ness of seismocardiography for the diagnosis of ischemia in 
patients with coronary artery disease. Ann Noninvasive Elec-
trocardiol 2005;10(3):281-7.
40. Payvar S, Eftekhari H, Munir MS, Ahmed AH, Asopa S, 
Sadeghi N, et al. Coronary sinus temperature and its waveform 
change during myocardial ischemia: candidate for monitoring 
devices [abstract]. Am J Cardiol 2004;94(Suppl 6A):201E.
41. Pislaru C, Anagnostopoulos PC, Seward JB, Greenleaf JF, 
Belohlavek M. Higher myocardial strain rates during isovolu-
mic relaxation phase than during ejection characterize acute-
ly ischemic myocardium. J Am Coll Cardiol 2002;40(8): 
1487-94.
42. Theres HP, Kaiser DR, Nelson SD, Glos M, Leuthold T, 
Baumann G, et al. Detection of acute myocardial ischemia 
during percutaneous transluminal coronary angioplasty by 
endocardial acceleration. Pacing Clin Electrophysiol 2004;27 
(5):621-5.
43. Osler W. The Principles and Practice of Medicine. 1st ed. 
New York: D. Appleton & Company; 1892.
44. Heart Failure Society of America. HFSA 2006 Comprehen-
sive Heart Failure Practice Guideline. J Card Fail 2006;12(1): 
e1-2.
45. Chin MH, Goldman L. Factors contributing to the hospital-
ization of patients with congestive heart failure. Am J Public 
Health 1997;87(4):643-8.
46. Michalsen A, Konig G, Thimme W. Preventable causative 
factors leading to hospital admission with decompensated 
heart failure. Heart 1998;80(5):437-41.
47. Shahar E, Lee S, Kim J, Duval S, Barber C, Luepker RV. Hos-
pitalized heart failure: rates and long-term mortality. J Card 
Fail 2004;10(5):374-9.
48. Nallamothu BK, Payvar S, Wang Y, Kosiborod M, Masoudi 
FA, Havranek EP, et al. Admission body temperature and 
mortality in elderly patients hospitalized for heart failure. J 
Am Coll Cardiol 2006;47(12):2563-4.
49. Friedman MM. Older adults’ symptoms and their duration 
before hospitalization for heart failure. Heart Lung 1997;26 
(3):169-76.
50. Schiff GD, Fung S, Speroff T, McNutt RA. Decompensated 
heart failure: symptoms, patterns of onset, and contributing 
factors. Am J Med 2003;114(8):625-30.
51. Lasater M, Von Rueden KT. Outpatient cardiovascular man-
agement utilizing impedance cardiography. AACN Clin Is-
sues 2003;14(2):240-50.
52. Packer M, Abraham WT, Mehra MR, Yancy CW, Lawless 
CE, Mitchell JE, et al.; Prospective Evaluation and Identifi-
cation of Cardiac Decompensation by ICG Test (predict) 
Study Investigators and Coordinators. Utility of impedance 
cardiography for the identification of short-term risk of clini-
cal decompensation in stable patients with chronic heart fail-
ure. J Am Coll Cardiol 2006;47(11):2245-52. 
53. Walton AS, Krum H. The Heartpod implantable heart fail-
ure therapy system. Heart Lung Circ 2005;14 Suppl 2:S31-3.
54. Casscells W, Vasseghi MF, Siadaty MS, Madjid M, Siddiqui 
H, Lal B, Payvar S. Hypothermia is a bedside predictor of im-
minent death in patients with congestive heart failure. Am 
Heart J 2005;149(5):927-33.
55. Ahmed A, Aboshady I, Munir MS, Brewer A, Lai D, Shankar 
KJ, et al. Body temperature fall predicts increased mortality 
and re-hospitalization in patients with congestive heart failure 
[abstract]. Am J Cardiol 2006;98(Suppl 8A):87M.
56. Cremers B, Kjellstrom B, Sudkamp M, Bohm M. Hemo-
dynamic monitoring during sexual intercourse and physical 
exercise in a patient with chronic heart failure and pulmonary 
hypertension. Am J Med 2002;112(5):428-30.
57. Adamson PB, Magalski A, Braunschweig F, Bohm M, Reyn-
olds D, Steinhaus D, et al. Ongoing right ventricular hemody-
namics in heart failure: clinical value of measurements derived 
from an implantable monitoring system. J Am Coll Cardiol 
2003;41(4):565-73.
58. Cleland JG, Coletta AP, Freemantle N, Velavan P, Tin L, 
Clark AL. Clinical trials update from the American College of 
Cardiology meeting: care-hf and the remission of heart fail-
Texas Heart Institute Journal Device-Based Monitoring of CHF      173
ure, Women’s Health Study, tnt, compass-hf, veritas, can-
pap, peech and premier. Eur J Heart Fail 2005;7(5):931-6.
59. Lane RE, Cowie MR, Chow AW. Prediction and prevention 
of sudden cardiac death in heart failure. Heart 2005;91(5): 
674-80.
60. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation 
1998;98(21):2334-51.
61. Lombardi G, Gallagher J, Gennis P. Outcome of out-of-hos-
pital cardiac arrest in New York City. The Pre-Hospital Ar-
rest Survival Evaluation (phase) Study. JAMA 1994;271(9): 
678-83.
62. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau 
R, et al.; Sudden Cardiac Death in Heart Failure Trial (SCD-
HeFT) Investigators. Amiodarone or an implantable cardio-
verter-defibrillator for congestive heart failure [published 
erratum appears in N Engl J Med 2005;352(20):2146]. N 
Engl J Med 2005;352(3):225-37.
63. Mushlin AI, Hall WJ, Zwanziger J, Gajary E, Andrews M, 
Marron R, et al. The cost-effectiveness of automatic implant-
able cardiac defibrillators: results from madit. Multicenter 
Automatic Defibrillator Implantation Trial. Circulation 1998; 
97(21):2129-35.
64. Kunavarapu C, Bloomfield DM. Role of noninvasive studies 
in risk stratification for sudden cardiac death. Clin Cardiol 
2004;27(4):192-7.
65. Shusterman V, Aysin B, Gottipaty V, Weiss R, Brode S, 
Schwartzman D, Anderson KP. Autonomic nervous system 
activity and the spontaneous initiation of ventricular tachy-
cardia. esvem Investigators. Electrophysiologic Study Versus 
Electrocardiographic Monitoring Trial. J Am Coll Cardiol 
1998;32(7):1891-9.
